Zhongshan Hospital, Xiamen University

Xiamen 361004

6 studies enrolling now · 12 studies all time

What they study most

Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD), Crohn Disease, Crohn's Disease, End Stage Kidney Disease, Esophageal Squamous Cell Carcinoma, Ischemic Stroke; Ischemic Attack, Transient, Moderately to Severely Active Crohns Disease, Moderately to Severely Active Ulcerative Colitis

Studies at this site

• A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) — Recruiting now
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Recruiting now
• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE — Running, not enrolling
• A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy — Running, not enrolling
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease — Running, not enrolling
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Completed